WASHINGTON (AP) — Federal officials on Thursday approved ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

A newly approved pain medication, suzetrigine, is the first nonopioid analgesic in 25 years to receive clearance from the U.S ...

Campaign finance reports for the seat won by Brach Myers of Lafayette show both candidates loaned their campaigns $200,000.

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and more.

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Driving the news: Journavx, from Vertex Pharmaceuticals ... adding he's been encouraged by signals from Washington that policymakers "really are trying to level the playing field." ...

The latest evidence of the disconnect is a Conference Board report Tuesday that consumer confidence plummeted 6.7% in February from January, the largest drop since 2021. The other major confidence ...

The additive manufacturing sector continues to show near-limitless potential. Innovations have taken 3D printers from creating customized figurines all the way to printing entire neighborhoods, ...

The stock's rise snapped a four-day losing streak.